Creative Medical Technology Holdings Reports Remarkable Study Results
Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) is making strides in the field of regenerative medicine, particularly in addressing chronic lower back pain. Recently, the company unveiled exciting mid-term follow-up data from its StemSpine® pilot study, confirming the successful application of AlloStem™, a cutting-edge cell therapy.
Results Highlight Substantial Opioid Reduction
The outcomes of the pilot study paint a promising picture for chronic pain sufferers. According to the data, an impressive 90% of the participants reported that they did not rely on opioids for pain management three years after undergoing the StemSpine® procedure. This significant drop is complemented by an enduring 80% reduction in pain scores and more than a 60% improvement in the Oswestry Disability Index, a commonly used measure for evaluating disability due to back pain.
Patient Outcomes and Safety Profile
Only one patient needed further intervention at the three-year follow-up, which speaks volumes about the safety and effectiveness of this innovative procedure. Importantly, there were no reported serious adverse events, reinforcing the favorable safety profile of StemSpine®.
Understanding the StemSpine® Procedure
StemSpine® is distinguished by its non-surgical, ultrasound-guided application of AlloStem™. This method utilizes allogenic (donor-derived) cells which are readily available, aiming to enhance healing and recovery in patients suffering from debilitating lower back pain. The proprietary nature of this technology, supported by a patented framework, broadens its potential applications in clinical settings.
The Vision of Creative Medical Technology Holdings
Timothy Warbington, the President and CEO of Creative Medical Technology Holdings, articulated the company’s commitment to tackling the opioid crisis faced by many lower back pain patients. He expressed that these findings validate the efficacy of AlloStem™ in the StemSpine® procedure, asserting, "This promising data supports our vision of providing innovative, non-surgical solutions for millions of Americans struggling with chronic lower back pain.”
Future Directions and Clinical Trials
The findings from the StemSpine pilot study play a significant role in the ongoing FDA-cleared Phase 1/2 ADAPT clinical trial for CELZ-201-DDT aimed at chronic lower back pain. Although the pilot results are independent of the ADAPT study, they have ignited robust interest and enrollment in this randomized, double-blind trial. The encouraging data further strengthens the position of StemSpine® as a pioneering therapy in regenerative medicine.
About Creative Medical Technology Holdings, Inc.
Creative Medical Technology Holdings is a trailblazer in biotechnology, focusing on innovative biological therapeutics across multiple specialties, including immunotherapy, endocrinology, urology, gynecology, and orthopedics. The company is dedicated to advancing medical solutions with a mission to enhance patient outcomes.
Frequently Asked Questions
What is the StemSpine® procedure?
The StemSpine® procedure is a patented, non-surgical method using ultrasound guidance to apply AlloStem™, a cell therapy aimed at alleviating chronic lower back pain.
What were the main findings from the recent study?
Over 90% of patients reported no opioid use three years after the procedure, with significant reductions in pain scores and disability index improvements.
How does AlloStem™ work?
AlloStem™ utilizes donor-derived cells to promote healing and regeneration in the affected areas of the spine, aiming to enhance recovery in chronic pain patients.
Is the StemSpine® procedure safe?
Yes, the procedure has shown a favorable safety profile, with no serious adverse events reported in the study.
What is the future for Creative Medical Technology Holdings?
The company continues to pursue clinical trials and advancements in regenerative medicine while striving to provide innovative non-surgical solutions for those with chronic conditions.
